PD-1 molecule for blocking binding of Anti-PD-1 antibody to PD-1 molecule on cell surface, and mutant and use thereof

AU2024384309A1Pending Publication Date: 2026-07-09SHENZHEN PREGENE BIOPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
SHENZHEN PREGENE BIOPHARMA CO LTD
Filing Date
2024-01-25
Publication Date
2026-07-09

AI Technical Summary

Technical Problem

Current anti-PD-1 antibody therapies for malignant tumors often cause immune-related adverse events (irAEs), with glucocorticoids being the primary treatment but having significant side effects, and existing drugs for irAEs are inadequate for all patients.

Method used

Development of a protein molecule with 80-100% sequence identity to wild-type PD-1, featuring specific amino acid substitutions at positions 126 or 134, which competitively binds to anti-PD-1 antibodies on T cells, blocking their interaction without affecting PD-L1 binding, thereby alleviating irAEs.

Benefits of technology

The protein molecule effectively competes with anti-PD-1 antibodies, restoring T-cell function and alleviating immune-related adverse events without blocking PD-L1, providing a novel approach for clinical treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided are a PD-1 molecule for blocking the binding of an anti-PD-1 antibody to a PD-1 molecule on a cell surface, and a mutant and the use thereof. Further provided is a protein molecule, which has 80-100% sequence identity to a wild-type protein as shown in SEQ ID NO: 1. The provided recombinant protein H126 and H134 molecules can competitively bind to an anti-PD-1 antibody drug with the endogenous PD-1 molecule expressed by a T cell, without affecting the binding of PD-1 to an endogenous PD-L1 molecule, thereby restoring the function suppression on activated T cells and alleviating the symptoms of immunotherapy-related adverse events. By means of the protein molecule, a new way of performing clinical treatment of the immunotherapy-related adverse events is provided.
Need to check novelty before this filing date? Find Prior Art